We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
151
Puma Biotechnology
PBYI
$406M
$2.01M 0.08%
+26,704
New +$2.53M
RIBT
152
DELISTED
RiceBran Technologies
RIBT
$1.98M 0.08%
90,197
+5,611
+7% +$157K
VASC
153
PUT
DELISTED
Vascular Solutions Inc
VASC
$1.97M 0.08%
+607
New +$21.7K
BCLI
154
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.95M 0.08%
56,823
+7,247
+15% +$341K
ZSPH
155
CALL
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$1.95M 0.08%
+297
New +$17.8K
DYAX
156
PUT
DELISTED
DYAX CORPORATION
DYAX
$1.94M 0.08%
1,017
+942
+1,256% +$22.5K
MCRB icon
157
Seres Therapeutics
MCRB
$46.5M
$1.92M 0.08%
+3,239
New +$2.64M
SRNE
158
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.91M 0.08%
+2,275
New +$36.2K
GMED icon
159
PUT
Globus Medical
GMED
$10.9B
$1.89M 0.08%
+913
New +$23.1K
TPST icon
160
PUT
Tempest Therapeutics
TPST
$13.9M
$1.87M 0.08%
+1
New +$67.3K
CYH icon
161
Community Health Systems
CYH
$393M
$1.86M 0.08%
+52,510
New +$2.41M
THMO
162
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$1.85M 0.08%
389
-23
-6% -$140K
CBPO
163
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$1.8M 0.07%
20,000
+15,000
+300% +$1.58M
QRHC icon
164
Quest Resource Holding
QRHC
$28.3M
$1.79M 0.07%
393,550
+10,026
+3% +$67.5K
XTLB
165
XTL Biopharmaceuticals
XTLB
$7.27M
$1.79M 0.07%
57,494
-55
-0.1% -$2.03K
FOMX
166
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.78M 0.07%
243,361
+67,361
+38% +$687K
ONCS
167
DELISTED
OncoSec Medical Incorporated
ONCS
$1.75M 0.07%
1,546
-1,944
-56% -$2.55M
IMUC
168
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$1.75M 0.07%
104,231
-42,564
-29% -$775K
ACUR
169
DELISTED
Acura Pharmaceuticals
ACUR
$1.75M 0.07%
+743,603
New +$2.53M
BLCM
170
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.75M 0.07%
12,009
-12,095
-50% -$2.22M
VXZ
171
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$1.74M 0.07%
334
-734
-69% -$34K
QURE icon
172
CALL
uniQure
QURE
$2.52B
$1.73M 0.07%
844
+462
+121% +$12.2K
SAGE
173
DELISTED
Sage Therapeutics
SAGE
$1.69M 0.07%
40,019
+14,939
+60% +$921K
TBRA
174
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$1.69M 0.07%
+174,943
New +$2.46M
NUVA
175
DELISTED
NuVasive, Inc.
NUVA
$1.69M 0.07%
+35,000
New +$1.81M
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.